TheraCryf Reaches Manufacturing Milestone for Ox-1 Addiction Programme

TheraCryf (LSE:TCF) has reported a significant manufacturing achievement for Ox-1, its lead orexin-1 receptor antagonist being developed for the treatment of addictive disorders. The company has successfully scaled up production of the active drug substance to 10.6kg, exceeding targeted yields and providing sufficient material to support upcoming 28-day regulatory toxicology studies in two animal species.

With maximum tolerated dose and dose range-finding studies now in progress, TheraCryf expects the formal toxicology programme to commence in the first half of 2026 and conclude in the third quarter. Completion of these studies would represent an important step toward clinical trial readiness and a subsequent regulatory submission. The company has also engaged with investors through a webinar outlining recent progress and highlighting potential value-driving milestones anticipated during 2026.

Despite these positive development updates, TheraCryf’s overall outlook remains constrained by ongoing financial losses and continued cash burn. Technical indicators are also negative, with the share price trading below key moving averages and a bearish MACD signal. While operational progress provides some balance, valuation metrics remain limited due to negative earnings and the absence of dividend support.

More about TheraCryf

TheraCryf plc is a clinical-stage drug development company focused on disorders of the brain. Its pipeline targets areas including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental conditions. TheraCryf’s business model centres on advancing programmes through preclinical and early clinical proof of concept before partnering with mid-sized or large pharmaceutical companies for later-stage development and commercialisation. The company is based at Alderley Park in Cheshire, is listed on AIM under the ticker TCF, and collaborates with industry and academic partners such as Stalicla SA, the University of Manchester, King’s College London and the University of Michigan.